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Introduction
A key step in the maturation of many secreted proteins and extra­
cellular domains of membrane proteins is the formation of di­
sulfide bonds in the ER. Disulfide bonds, which stabilize native 
and functional conformations of proteins, are formed by pairing 
and oxidation of cysteines during the initial folding process in 
the ER. In Saccharomyces cerevisiae, most biosynthetic disul­
fide bonds are formed by dithiol/disulfide transfer reactions 
with the oxidized form of protein disulfide isomerase (PDI), 
Pdi1p (Sevier and Kaiser, 2002; Wilkinson and Gilbert, 2004). 
Pdi1p, in turn, requires other oxidizing molecules to be recycled 
because Pdi1p cannot generate disulfide bonds by itself. We 
and other colleagues identified the major disulfide­generating 
flavoenzyme Ero1p in S. cerevisiae (Frand and Kaiser, 1998; 
Pollard et al., 1998). In both yeast and mammalian cells, Ero1 
directly transfers disulfide bonds to PDI (Frand and Kaiser, 2000; 
Mezghrani et al., 2001). The oxidative capacity of the yeast ER 
depends primarily on the activity of Ero1p: a temperature­sensitive 
ero1-1 mutation decreases the resistance of yeast to the reducing 
agent DTT and induces the unfolded protein response with ac­
cumulation of secretory proteins, and, after prolonged incubation 
at the restrictive temperature, a strain with this mutation loses 
viability (Frand and Kaiser, 1998, 1999; Cuozzo and Kaiser, 1999; 
Tu and Weissman, 2002), and overexpression of ERO1 from 
a multicopy plasmid increases the oxidizing capacity of yeast 
cells, as shown by their increased resistance to DTT (Frand and 
Kaiser, 1998).
The catalytic cycle of Ero1p depends on a relay of disulfide 
bonds from the conserved active­site cysteine pair, C352­C355, 
which is proximal to bound flavin adenine dinucleotide (FAD) 
to the second shuttle cysteine pair, C100­C105, which is respon­
sible for direct disulfide transfer to Pdi1p (Frand and Kaiser, 
2000; Gross et al., 2004; Sevier and Kaiser, 2006b). In addition 
to these two catalytic cysteine pairs, Ero1p contains three cyste­
ine pairs (C90­C349, C143­C166, and C150­C295) that form 
regulatory bonds (Sevier et al., 2007). Several lines of evidence 
indicate that Ero1p is inactive with regulatory bonds formed, 
whereas it is active with regulatory cysteines in the reduced 
state. Ero1p is converted from an oxidized (inactive) state to the 
reduced (active) state in the presence of reduced thioredoxin­1 
(Trx1) as a substrate; once Trx1 is fully oxidized through the 
action of active Ero1p, Ero1p returns to the oxidized (inactive) 
form (Sevier et al., 2007). A double mutant, Ero1p­C150A­C295A, 
which cannot form the crucial C150­C295 regulatory bond, 
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et al., 2008). We have reconstituted this coupled reaction in vitro 
and show that it recapitulates properties of the ER in vivo; as 
long as an excess of reduced glutathione is available, Pdi1p is 
maintained in a state enabled to activate Ero1p, which in turn 
provides oxidizing equivalents to oxidize glutathione.
Results
Ero1p is capable of autonomous 
inactivation
Because the regulatory bonds link distant sites of the Ero1p 
polypeptide chain, the presence or absence of these bonds can 
be readily discerned by mobility differences on nonreducing 
SDS­PAGE (Fig. 1 A). Activity of Ero1p can be inferred from 
the redox state of the regulatory bonds. In live yeast cells, Ero1p 
is converted to the reduced (active) form in cells treated with 
the reducing agent DTT and then returns to the oxidized (inactive) 
form after DTT removal (Fig. 1 B). Activation of Ero1p by re­
duction of the regulatory bonds and subsequent inactivation 
by reformation of the regulatory bonds could also be readily 
observed in an in vitro assay containing recombinant Ero1p 
(Ero1pc, 56–424, with an N­terminal (1–55) and a C­terminal 
(425–563) fragment removed) and an excess of reduced Trx1, 
exhibits increased Ero1p activity in vitro and in vivo (Sevier 
et al., 2007).
A byproduct of Ero1p activity is the generation of hydro­
gen peroxide as a result of a two­electron reduction of oxygen 
per disulfide generated. Thus, although Ero1p activity is essential 
for biosynthetic disulfide bond formation, uncontrolled Ero1p 
activity could produce too much reactive oxygen species that 
would be detrimental to the cell (Gross et al., 2006). Indeed, 
overexpression of the hyperactive Ero1p­C150A­C295A mutant 
inhibits cell growth, highlighting the physiological importance 
of the regulatory bonds in keeping Ero1p activity in check. 
Mammalian Ero1­ has been shown to modulate its activity 
through a similar mechanism involving regulatory bonds, show­
ing that autoregulation in response to the redox environment is a 
general property of Ero1 (Appenzeller­Herzog et al., 2008; Baker 
et al., 2008). An additional layer of protection against reactive 
oxygen accumulation in the ER of mammalian cells is provided by 
an ER resident, peroxiredoxin, which reduces hydrogen peroxide 
generated by Ero1 to limit peroxide accumulation (Tavender et al., 
2008, 2010; Zito et al., 2010). An obvious sequence homolog to 
peroxiredoxin is absent in yeast; whether additional pathways 
functionally similar to the peroxiredoxin system exist in the ER of 
fungi remains to be explored.
The precise mechanism by which the regulatory bonds of 
Ero1 are reduced and then reoxidized will be crucial to under­
stand how Ero1p activity is controlled and which features of the 
redox environment of the ER are sensed by Ero1p. Pdi1p is the 
most abundant oxidoreductase of the yeast ER and is the pre­
ferred physiological substrate for oxidation by Ero1p (Nørgaard 
et al., 2001; Vitu et al., 2010); therefore, Pdi1p is likely to play 
an important part in regulating Ero1p. In the mammalian ER, 
the disulfide relay between Ero1­ and PDI is regulated at least 
in part by the availability of PDI (Appenzeller­Herzog et al., 
2010; Inaba et al., 2010). Interaction between Ero1­ and PDI 
has been shown to be facilitated by a protruding ­hairpin 
in Ero1­ and the b domain of PDI, which facilitates the inter­
conversion between the Ox1 and Ox2 redox­active forms of 
Ero1­ (Masui et al., 2011). Differences between Ero1­ and 
Ero1p, including the lack of a ­hairpin in Ero1p and the prefer­
ence of Ero1p for the a domain of Pdi1p (versus the preference of 
Ero1­ for the a domain), suggest that the yeast and mam­
malian Ero1­PDI systems may operate differently.
In vitro assays showing activation of Ero1p have typically 
used the nonphysiological substrate Trx1, which has a single 
CxxC­containing domain with a highly reducing reduction po­
tential rather than the physiological substrate Pdi1p because re­
duced Trx1 is more effective than Pdi1p at activating Ero1p by 
reduction of regulatory bonds (Sevier et al., 2007; Baker et al., 
2008; Vitu et al., 2010). Here, we examine the role of Pdi1p in the 
reduction and reoxidation of the Ero1p regulatory bonds to 
reveal how the activity of Ero1p is set in a living cell. We have also 
sought to understand the role of glutathione in this process as the 
most abundant redox buffer of the ER. Although glutathione 
itself does not activate Ero1p nor is glutathione efficiently used as 
a substrate for Ero1p (Tu et al., 2000; Sevier and Kaiser, 2006b), 
reduced glutathione can stimulate Ero1p activity when used in 
conjunction with Pdi1p as a substrate (Sevier et al., 2007; Baker 
Figure 1. Ero1p regulation by reduction or oxidation of its regulatory 
bonds. (A) Disulfide connectivity of Ero1p and Pdi1p. In Ero1p, dark gray 
and light gray circles indicate catalytic and regulatory cysteines, respec-
tively. Pdi1p has four thioredoxin domains, a, b, b, and a. In Pdi1p, 
dark gray and black circles indicate catalytic and structural cysteines, 
respectively. (B) Ero1p cycles between oxidized (ox) and reduced (red) 
regulatory states in vivo according to the redox environment. Cells were 
incubated with 0, 0.2, or 1 mM DTT for 30 min. DTT was removed by 
placing cells in fresh medium. (C) Ero1p regulation in vitro. 1 µM Ero1pc 
was incubated with 50 µM reduced Trx1.
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and oxidized forms likely correspond to partially oxidized 
states of Ero1pc. Parallel reactions using Ero1pc mutants lack­
ing the shuttle disulfide bond (Ero1pc­C100A­C105A) or the 
catalytic disulfide bond (Ero1pc­C355S) in the absence of Trx1 
exhibited greatly slowed or no autonomous reoxidation of 
Ero1pc, respectively (Fig. 2 B, middle and bottom). In addition, 
when the reoxidation reaction was performed in the absence of 
O2 as an electron acceptor (Fig. S1 A, right), Ero1pc exhibited 
slowed autonomous reoxidation. These observations show that 
Ero1pc is capable of autonomous oxidation to form regulatory 
bonds and that this oxidation has catalytic requirements similar 
to biosynthetic disulfide bond formation.
We considered the possibility that autonomous oxidation 
of the Ero1p regulatory bonds was promoted by the hydrogen 
peroxide generated by Ero1pc before removal of Trx1. There­
fore, we examined the effects of hydrogen peroxide. Addition 
of catalase to the reaction, which should convert any hydrogen 
peroxide into water and oxygen (Fig. S1 B), did not signifi­
cantly slow autonomous oxidation of the Ero1p regulatory bonds 
(Fig. S1 A, middle). Conversely, addition of 100 µM hydro­
gen peroxide, the maximum concentration that could be obtained 
from complete oxidation of 100 µM Trx1, did not enhance the 
oxidation of Ero1pc­C100A­C105A (Fig. S1 C).
Autonomous oxidation of Ero1p occurs via 
an intermolecular reaction
Autonomous oxidation of Ero1p could conceivably occur by 
intramolecular (in cis) or intermolecular (in trans) disulfide bond 
transfer. In the crystal structure of Ero1pc (Gross et al., 2004), 
one of the regulatory bonds, C90­C349, is close enough to the 
catalytic site to be oxidized in cis, whereas the other two regula­
tory bonds, C150­C295 and C143­C166, are located >20 Å away 
from the catalytic site, suggesting that the oxidation of these 
serving as an effective substrate for Ero1p (Fig. 1 C). First, 
Ero1pc is inactive with the regulatory bonds in a fully oxidized 
state. In 0.5 min after addition of reduced Trx1, the regulatory 
bonds of Ero1pc become reduced, and Ero1pc is thus activated 
for the oxidation of Trx1. As a consequence of Ero1pc, after 
60 min, all of the Trx1 is oxidized, and Ero1pc returns to the 
oxidized inactive form (Fig. 1 C).
Activation of Ero1pc by reduction of the regulatory bonds 
initiates on addition of reduced Trx1, indicating that the regu­
latory bonds can be reduced by direct dithiol/disulfide ex­
change with reduced Trx1. For the end phase of the reaction in 
which most of the Trx1 is oxidized and the regulatory bonds of 
Ero1pc become reoxidized, we wished to know whether reoxi­
dation of the regulatory bonds occurred by direct oxidation by 
oxidized Trx1 or instead by autonomous reoxidation by Ero1p 
when all of the reduced Trx1 had been consumed. To distin­
guish between these possibilities, we first tested the ability of 
active Ero1pc to oxidize regulatory cysteines in the absence of 
Trx1. For this experiment, 1 µM Ero1pc was incubated with 
100 µM His6­tagged reduced Trx1 for 2 min, a time sufficient 
for complete activation of Ero1pc by reduction of the regula­
tory bonds. Subsequently, His6­tagged Trx1 was removed by 
affinity to Ni2+ beads (Fig. 2 A). Trx1 depletion was confirmed 
by the significant absence of Trx1 in the Ni2+ unbound fraction 
and corresponding presence of Trx1 bound to the Ni2+ beads 
(unbound faction; Fig. 2 A, bottom). A small amount of residual 
Trx1 was observed in the unbound fraction (Fig. 2 A, bottom), 
but it was anticipated that this limited fraction of Trx1 would 
be rapidly oxidized by Ero1pc and not contribute to our Ero1pc 
inactivation assay. After depletion of reduced Trx1, Ero1pc 
was converted from a fully reduced to an oxidized form over a 
period of 60 min with a half time for completion of 10 min 
(Fig. 2 B, top). The bands migrating between the fully reduced 
Figure 2. Pathways for Ero1p inactivation. (A) To 
test the ability of Ero1p to oxidize itself autono-
mously, 1 µM reduced (red) Ero1pc was prepared 
by incubation with 100 µM reduced His6-tagged 
Trx1 for 2 min and then passage through Ni2+ beads 
to remove Trx1. Trx1 depletion was confirmed by 
SDS-PAGE (Mix; initial mixture: Ni2+-BF [beads 
bound fraction] and Ni2+-UF [unbound fraction]). 
(B) Autonomous reoxidation (ox) of Ero1pc after 
removal of Trx1 occurs rapidly and efficiently but 
depends on a functional active site (C355), and ef-
ficient reoxidation depends on the shuttle disulfide 
(C100-C105). The first lane in each time course 
() shows the oxidation state of Ero1pc before re-
duction by Trx1. (C) Ero1pc, expressed as an MBP 
fusion (MBP-Ero1pc), can reoxidize Ero1pc-C355S 
in trans. An equal mixture of MBP-Ero1pc (or MBP-
ero1-C100A-C105A; right) and Ero1pc-C355S 
was reduced by incubation with reduced Trx1 
followed by Trx1 depletion. The time course of reox-
idation of MBP-Ero1pc and Ero1pc-C355S was fol-
lowed independently by separating MBP-Ero1pc and 
Ero1pc-C355S by size in SDS-PAGE and immuno-
blotting for MBP or Ero1.
 o
n
 April 18, 2012
jcb.rupress.org
D
ow
nloaded from
 
Published March 12, 2012
JCB • VOLUME 196 • NUMBER 6 • 2012 716
oxidized (Fig. S2) and Trx1 that was almost fully in the oxidized 
form (not depicted). We found that addition of a 20­fold molar 
excess of oxidized Trx1 had no effect on the rate of reoxida­
tion of Ero1pc­C100A­C105A (Fig. 3 A, top), showing that 
oxidized Trx1 has little or no capability to oxidize the regula­
tory bonds of Ero1p. In contrast, oxidized Pdi1p dramatically 
increased the rate of Ero1pc­C100A­C105A reoxidation (Fig. 3 A, 
top right). The ability of oxidized Pdi1p to efficiently oxidize 
the regulatory bonds of Ero1p was not a peculiarity of the 
Ero1pc­C100A­C105A mutant, as we could also show that 
oxidized Pdi1p accelerated the oxidation of wild­type Ero1pc 
as well as Ero1pc­C355S, which is unable to oxidize its regula­
tory bonds (Fig. S3). These results show that Ero1p can be in­
activated by direct feedback from Pdi1p.
Next, we tested the converse process, the ability of re­
duced Pdi1p to reduce and thus activate Ero1p. To assess the 
activation process selectively, we again used Ero1pc­C100A­
C105A because of this mutant’s greatly diminished capacity for 
autonomous oxidation of regulatory cysteines once reduced 
with an exogenous agent (Fig. 2 B, middle). Reduced Pdi1p re­
quires 60 min to reduce the Ero1p regulatory bonds completely, 
whereas reduced Trx1 requires <5 min, indicating that Pdi1p is 
a relatively poor activator of Ero1p (Fig. 3 B, top). In summary, 
Trx1 is a potent activator but poor inactivator of Ero1p, whereas 
Pdi1p is a weak activator but potent inhibitor of Ero1p. These 
contrasting abilities to reduce or oxidize the regulatory bonds of 
Ero1p can be accounted for by the much greater reducing po­
tential of Trx1 as compared with Pdi1p. By assaying the rate of 
activation or inactivation of Ero1p in separate reactions, we 
could show that reduced Pdi1p activates Ero1p more slowly 
than oxidized Pdi1p can inactivate Ero1p. This explains why in 
an in vitro Ero1p oxidation reaction that contains reduced Pdi1p 
as a substrate, Ero1p rarely, if ever, becomes fully activated, 
and the reaction proceeds relatively slowly.
The a and a domains of Pdi1p differ  
in their ability to regulate Ero1p
Yeast Pdi1p has two redox­active thioredoxin­like domains with 
different reduction potentials: the a domain (195 mV) and a 
domain (164 mV; Fig. 1 A; Tian et al., 2006; Vitu et al., 2010). 
We recently showed that Ero1p preferentially oxidizes the a 
domain both in vivo and in vitro, suggesting Ero1p provides oxi­
dizing equivalents to the ER mainly via the a domain (Vitu et al., 
2010). Thus, the a domain may play a lesser role in the oxida­
tion of ER substrates despite its higher reduction potential than 
the a domain. To fully understand the interactions between Pdi1p 
and Ero1p, we wished to evaluate the contribution of each of the 
active Pdi1p domains to reduction and oxidation of Ero1p regu­
latory bonds.
Recombinant Pdi1p purified from E. coli had a fully oxidized 
a domain and a partially oxidized a domain (Fig. S2), consistent 
with the different reduction potentials of the two domains. More­
over, naturally oxidized purified domain mutants Pdi1p­CCSS 
(a domain cysteines intact) and Pdi1p­SSCC (a domain cyste­
ines intact) had similar oxidation states to the corresponding 
domains in wild­type Pdi1p (unpublished data). The same assay 
for Pdi1p oxidation of the Ero1p regulatory bonds was performed 
bonds would require involvement of additional dithiol/disulfide 
exchanges with other cysteines. To determine whether one Ero1p 
protein can oxidize the regulatory bonds of another Ero1p, we 
asked whether Ero1pc­C355S, which is catalytically inactive 
and is not capable of autonomous oxidation, could nevertheless 
be oxidized in trans by active Ero1pc. A maltose binding pro­
tein (MBP) fusion to Ero1pc was used in this experiment so that 
MBP­Ero1pc and Ero1pc­C355S could be distinguished by 
their distinct mobilities on SDS­PAGE. An autonomous oxida­
tion assay was established by combining MBP­Ero1pc and 
Ero1pc­C355S with reduced Trx1 to reduce the regulatory bonds 
on both forms of Ero1p. After Trx1 was removed by Ni2+ affinity, 
both Ero1pc­C355S and MBP­Ero1pc were reoxidized at nearly 
equal rates, showing that efficient trans oxidation can occur 
(Fig. 2 C). Consistent with the oxidation of Ero1pc­C355S 
being a product of MBP­Ero1pc catalytic function, disruption 
of the MBP­Ero1p catalytic cycle by mutating the C100­C105 
pair (MBP­ero1­C100A­C105A) prevented Ero1pc­C355S oxi­
dation (Fig. 2 C). We also tested the effect of dilution of Ero1pc 
in our autonomous oxidation assay and found that a fourfold 
dilution of Ero1pc slowed autonomous oxidation of Ero1pc 
(unpublished data). Together, the trans oxidation experiment and 
the dilution experiment show that autonomous oxidation of the 
Ero1p regulatory disulfides occurs predominantly, if not exclu­
sively, by one Ero1p protein oxidizing the regulatory bonds of 
another Ero1p. The simplest mechanism for such dithiol/disul­
fide exchange would be for successive direct transfer of the 
C100­C105 shuttle cysteine disulfide bond to each of the three 
regulatory cysteine pairs. However, we cannot rule out the pos­
sibility that more complicated dithiol/disulfide rearrangements 
occur. Slow oxidation of Ero1pc facilitated by the Ero1pc­
C100A­C105A (but not the Ero1pc­C355S) mutant could be 
observed also at late time points of the autonomous oxidation 
assay (>20 min), suggesting that the C352­C355 active site may 
contribute directly to oxidation of Ero1pc.
Ero1p is activated slowly but inactivated 
rapidly by Pdi1p
As we have shown, reduced Trx1 is a potent activator of Ero1p, 
and the use of Trx1 as an activator and substrate for Ero1p in 
in vitro assays made it possible to document the dramatic effect 
that reduction and oxidation of regulatory cysteines have on Ero1p 
activity (Fig. 1 C; Sevier et al., 2007). However, Pdi1p is the major 
physiological substrate of Ero1p (Frand and Kaiser, 1999), and 
we were interested to use the in vitro assay for Ero1p regulation 
to make a comparable assessment of the ability of Pdi1p to 
either activate or inactivate Ero1p activity through reduction or 
oxidation of regulatory bonds.
First, we tested the ability of oxidized Pdi1p to inactivate 
Ero1p. We prepared activated Ero1pc­C100A­C105A by treat­
ment with reduced Trx1 followed by removal of Trx1. The use 
of the Ero1pc­C100A­C105A mutant prevented efficient auton­
omous reoxidation of Ero1p, allowing us to test the ability of 
exogenous agents to reoxidize Ero1p. Oxidized Pdi1p and Trx1 
were prepared by air oxidation during purification from Esche-
richia coli. The endpoint of air oxidation yielded Pdi1p that had 
the a domain almost fully oxidized and the a domain 50% 
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both reduced Pdi1p­CCSS and reduced Pdi1p­SSCC reduced 
Ero1p regulatory bonds at similar rates (Fig. 3 B, bottom). As 
expected, the single­domain mutants reduced the Ero1p regula­
tory bonds somewhat less efficiently than did wild­type Pdi1p, 
which has both active sites intact, and the double domain 
mutant Pdi1p­SSSS did not reduce the Ero1p regulatory bonds 
(Fig. 3 B, bottom right).
The redox state of Ero1p can be set by a 
mix of reduced and oxidized Pdi1p
Reduced and oxidized Pdi1p promote activation and inactivation 
of Ero1p, respectively, suggesting that the activity of Ero1p in 
steady state may be set by the ratio of reduced to oxidized Pdi1p. By 
taking advantage of Ero1pc­C100A­C105A, which lacks the abil­
ity to oxidize Pdi1p efficiently, we could test admixtures of 
oxidized and reduced Pdi1p for their effect on the steady­state 
redox balance of the regulatory bonds of Ero1pc­C100A­C105A. 
with Pdi1p­CCSS or Pdi1p­SSCC mutants. Both Pdi1p mutants 
accelerated oxidation of the Ero1p regulatory bonds. Despite 
the less­active disulfides, Pdi1p­SSCC reproducibly accelerated 
Ero1p oxidation more rapidly than Pdi1p­CCSS (Fig. 3 A), con­
sistent with the higher reduction potential of the a CxxC. 
A Pdi1p­SSSS that lacked both redox­active sites did not acceler­
ate oxidation of Ero1p regulatory bonds to the extent of the 
other Pdi1p variants, but a modest acceleration of Ero1p oxida­
tion was observed (Fig. 3 A, bottom right). It is possible that the 
structural (CX6C) disulfide in Pdi1p (Fig. 1 A) has some effect 
or that Pdi1p may stabilize the oxidized form of Ero1p through 
a mechanism not involving disulfide exchange with the redox­
active motifs.
Next, we compared the ability of reduced Pdi1p­CCSS or 
Pdi1p­SSCC to reduce the regulatory bonds of Ero1pc­C100A­
C105A. Although reduction potentials measured against a glu­
tathione standard suggest that the a domain is a better reductant, 
Figure 3. Regulation of Ero1p by Pdi1p. (A) Reoxida-
tion (ox) of Ero1pc-C100A-C105A, which is impaired 
for autonomous oxidation, can be stimulated by oxidized 
Pdi1p but not by oxidized Trx1. Ero1pc-C100A-C105A 
was reduced (red) by incubation with reduced Trx1 fol-
lowed by Trx1 depletion. Reoxidation of Ero1pc-C100A-
C105A was followed after addition of a 20-fold molar 
excess of either oxidized Trx1 (ox-Trx1), oxidized Pdi1p 
(ox-PDI), or oxidized Pdi1p variants (a mutant–ox-CCSS, 
a mutant–ox-SSCC, and both the a and a mutant–SSSS). 
(B) Reduced Pdi1p is capable of reducing Ero1pc-C100A-
C105A albeit at a slower rate than reduction by reduced 
Trx1. Ero1pc-C100A-C105A was incubated with a 20-
fold excess of reduced Trx1 (red-Trx1), reduced Pdi1p 
(red-Pdi1p), or reduced Pdi1p variants (the red-Pdi1p 
panel is presented again in Fig. 4 C). (C) Oxidized Ero1pc-
C100A-C105A was mixed with different admixtures of 
reduced and oxidized Pdi1p for 1 h (the time required for 
100% reduced Pdi1p to reduce Ero1pc-C100A-C105A). 
The relative amounts of reduced, partially reduced, and 
oxidized Ero1pc-C100A-C105A were quantified by 
band intensity.
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First, the autonomous oxidation of Ero1p regulatory 
bond mutants Ero1pc­C150A­C295A, Ero1pc­C90A­349A, and 
Ero1pc­C143A­166A was evaluated for their ability to undergo 
autonomous reoxidation after being reduced by Trx1. This com­
parison is complicated by differing band mobility for the oxidized 
and partially oxidized states of each of the mutants (Fig. 4 A). 
As a measure of the oxidation rate that could be consistently 
applied to each of the mutants, we represented the progression 
of the oxidation process as the decline in the fraction of Ero1p 
that was in a fully reduced state. All regulatory mutants showed 
similar overall autonomous oxidation rates (Fig. 4 B), indicat­
ing that formation of the C150­C295 bond does not significantly 
affect oxidation of other regulatory bonds. Because the pattern 
of partially oxidized states was more complex for wild type 
(Fig. 2 B) than for the mutants, it was not possible to make a 
precise quantitative comparison of rates.
Next, we tested each of the three regulatory bond mutants 
for their ability to be activated by reduced Pdi1p. This test re­
quired addition of the shuttle cysteine mutant to each of the three 
regulatory bond mutants. Reduction of Ero1pc­C100A­C105A­
C150A­C295A by reduced Pdi1p was significantly faster than for 
Ero1pc­C100A­C105A or for the other regulatory bond mutants 
(Fig. 4, C and D). Ero1pc­C100A­C105A­C90A­C349A also 
Although accurate quantitative amounts cannot be obtained as a 
result of the complications that oxidized Pdi1p contains a partially 
reduced domain and also nonlinear detection by immunoblot analy­
sis, we found that when the fraction of reduced Pdi1p was >0.8, 
most Ero1pc­C100A­C105A was fully reduced, whereas when the 
fraction of reduced Pdi1p was <0.3, most Ero1pc­C100A­C105A 
was oxidized (Fig. 3 C). In a steady state, in vivo Pdi1p is partially 
reduced (Vitu et al., 2010) like air­oxidized recombinant Pdi1p, 
and almost all Ero1p is in a fully oxidized form (see 0 time point of 
Figs. 1 B and 5 E). Therefore, we could conclude that partially 
reduced Ero1pc is at least partially active and will continue to 
oxidize Pdi1p until a ratio of oxidized­to­reduced Pdi1p is achieved 
that no longer facilitates reduction and activation of Ero1p.
An Ero1p regulatory mutant is rapidly 
activated by Pdi1p
Previously, we showed that an Ero1p mutant that lacks only one 
of the three regulatory bonds, Ero1p(c)­C150A­C295A, has high 
enzymatic activity both in vivo and in vitro (Sevier et al., 2007; 
Vitu et al., 2010). This suggests that in the absence of the C150­
C295 regulatory bond, Ero1p is either more readily activated by 
reduced Pdi1p or less easily inactivated by reaction with oxidized 
Pdi1p or by autonomous oxidation.
Figure 4. Mutational analysis of the roles of individual regulatory bonds in autonomous reoxidation of Ero1p. (A) Ero1pc-C150A-C295A, Ero1pc-C90A-
C349A, or Ero1pc-C143-C166A was reduced (red) by incubation with reduced Trx1 followed by Trx1 depletion and the oxidation (ox) state analysis. 
(B) The fraction of reduced Ero1p was calculated by the ratio of the band intensity of reduced Ero1p species to the sum of fully reduced and fully oxidized 
band intensities. (C) Mutational analysis of the roles of individual regulatory bonds in reduction by reduced Pdi1p of Ero1pc-C100A-C105A. The respec-
tive mutants were incubated with a 20-fold excess of reduced Pdi1p followed by the oxidation state analysis (the result of Ero1pc-C100A-C105A was 
reproduced from Fig. 3 B). (D) The fraction of reduced Ero1p determined as in B reveals that the greatest rate enhancement occurs as a consequence of 
elimination by mutation of the C150-C295 disulfide bond.
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the crude immunoprecipitate by mass spectroscopy identified 
Pdi1p peptides but failed to identify additional PDI family 
members, including Eps1p, Eug1p, Mpd1p, or Mpd2p (unpub­
lished data). This result suggests that Pdi1p is the primary oxi­
doreductase engaged in oxidation or reduction of the Ero1p 
regulatory bonds. Loss of any single regulatory cysteine pair in 
Ero1p­C100A­C105A did not prevent trapping of a mixed di­
sulfide bond between Ero1p­C100A­C105A and Pdi1p, indicat­
ing that Pdi1p interaction with Ero1p­C100A­C105A is not 
limited to a single regulatory cysteine pair (Fig. 5 A). The mixed 
disulfides between Pdi1p and the various Ero1p­C100A­C105A 
regulatory bond mutants showed distinct mobilities on SDS­
PAGE (Fig. 5 A), which likely corresponded to different vari­
able combinations of cysteines in Ero1p and Pdi1p that engaged 
in oxidation and reduction of Ero1p regulatory bonds.
If reduced Pdi1p were essential for activating Ero1p, de­
pletion of Pdi1p from the ER would be expected to decrease 
activation of Ero1p by reduction of regulatory bonds even under 
prevailing reducing conditions in the ER. We have established 
conditions to deplete a cell of Pdi1p, which is essential for via­
bility, by glucose repression for 15 h of PGAL1-PDI1 in a pdi1 
genetic background (Fig. 5 B; Tachibana and Stevens, 1992; 
Frand and Kaiser, 1999). As expected, Pdi1p depletion disrupts 
folding in the ER, as shown by the accumulation of the ER form 
of carboxypeptidase Y (CPY), similar to that in cells that had 
been treated with DTT (Fig. 5 C). Radiolabeling of cells to spe­
cifically follow CPY synthesized after Pdi1p depletion confirmed 
a complete block of biosynthetic disulfide bond formation in 
newly synthesized CPY (Fig. S4). However, under the same condi­
tions of Pdi1p depletion, most Ero1p remains oxidized (Fig. 5 D), 
indicating that the signal for an insufficiently oxidized ER 
exhibited slightly faster reduction than Ero1pc­C100A­C105A or 
Ero1pc­C100A­C105A­C143A­C166A (Fig. 4, C and D). These 
results suggest that removal of the C150­C295 regulatory bond 
lowers the threshold for Ero1p activation. Interestingly, both 
the Ero1pc­C100A­C105A­C150A­C295A and Ero1pc­C100A­
C105A­C90A­C349A mutants exhibited some reoxidation of 
Ero1p (Fig. 4 C) and oxidation of Pdi1p (not depicted) at the 
60­min time point, suggesting that Ero1p may have alternative 
pathways to relay disulfide bonds to Pdi1p when the shuttle disul­
fide is unavailable (see Discussion).
Pdi1p is the primary in vivo regulator  
of Ero1p
If Pdi1p regulates Ero1p through reduction and oxidation of its 
regulatory bonds, it should be possible to trap mixed disulfide 
complexes between Pdi1p and the regulatory cysteines of Ero1p 
in vivo. To specifically isolate mixed disulfides with regulatory 
cysteines, we used FLAG epitope–tagged Ero1p­C100A­C105A 
(expressed ectopically in cells that carry wild­type ERO1). Ero1p­
C100A­C105A is unable to support yeast viability as a result of 
the disruption of its ability to oxidize Pdi1p in what has been 
shown to be the primary pathway for electron exchange be­
tween Pdi1p and Ero1p in living cells (Frand and Kaiser, 2000). 
Therefore, any observable mixed disulfides trapped between 
Ero1p­C100A­C105A and Pdi1p in living cells would likely 
represent thiol/disulfide exchange between the Ero1p regula­
tory cysteines and Pdi1p.
Ero1p­C100A­C105A­FLAG, isolated from cysteine­
alkylated cell extracts by immunoprecipitation with FLAG 
antibody, formed a predominant mixed disulfide complex that 
also reacted with Pdi1p antiserum (Fig. 5 A, lane 2). Analysis of 
Figure 5. Pdi1p-mediated Ero1 regulation 
in vivo. (A) Pdi1p forms mixed disulfide with 
the Ero1p regulatory cysteines. Ero1p-C100A-
C105A-Flag and its variants were immunopre-
cipitated (IP) by anti-flag antibody and analyzed 
by immunoblots against anti-flag antibody and 
anti-Pdi1p serum. Lane 1, Ero1p-C100A-C105A-
Myc; lane 2, Ero1p-C100A-C105A-flag; lane 3, 
Ero1p-C100A-C105A-C90A-C349A-flag; lane 4, 
Ero1p-C100A-C105A-C143A-C166A-flag; lane 
5, Ero1p-C100A-C105A-C150A-C295A-flag. The 
single asterisk indicates a monomer of Ero1p mu-
tants, and the double asterisks indicate mixed di-
sulfides between Ero1p mutants and Pdi1p. WB, 
Western blot. (B) Pdi1p was depleted by growing 
pdi1 covered with PGAL1-PDI1 in SMM (glucose 
medium) for 15 h. (C) Immature CPY accumulates 
as Pdi1p is depleted. A control for fully reduced 
environment was prepared by treating cells with 1 
mM DTT for 1 h. m, mature CPY; p1/p2, nascent 
and glycosylated CPY, respectively. (D) Oxidation 
(ox) states of Ero1p after Pdi1p depletion (glucose 
medium) in a genetic background with pdi1 or 
with pdi1 with deletions of all PDI homologs (PDI 
homolog-). red, reduced. (E) The roles of Pdi1p or 
glutathione on in vivo activation of Ero1p. Pdi1p-
depleted cells (middle) and glutathione-depleted 
cells (right) were prepared by growing CKY1081 
in glucose medium and in galactose medium with 
5 mM BSO, respectively. Cells were treated with 
2 mM DTT for the indicated time.
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a pool of reduced glutathione (GSH) in the ER, which in turn 
could lead to reduction of Pdi1p. To test the possibility that 
DTT acts indirectly through glutathione, we tested the effect of 
depleting cells of glutathione by treating cells with 5 mM buthi­
onine sulfoximine (BSO) for 15 h, which blocks glutathione 
synthesis by inhibiting ­glutamylcysteine synthetase. Reduction 
of Ero1p regulatory bonds by DTT treatment occurred more slowly 
in glutathione­depleted cells than in untreated cells (Fig. 5 E). 
This result suggests that the presence of a reducible pool of glu­
tathione may accelerate the overall process of reduction of Pdi1p 
by DTT. Alternatively, depletion of glutathione by BSO treat­
ment may subtly affect Pdi1p expression or have some other 
indirect effect on the redox state of the ER.
To address the role of glutathione in Ero1p activation more 
directly, we reconstituted Ero1p activation in vitro using both 
Pdi1p and GSH as substrates. By itself, Pdi1p is a poor activator of 
Ero1p because once Pdi1p has become oxidized through Ero1p 
oxidase activity, there is no longer sufficient reduced Pdi1p avail­
able to keep Ero1p in an active state, and oxidized Pdi1p can 
accelerate inactivation of Ero1p. Therefore, fully activated Ero1p 
was rarely observed during reaction with reduced Pdi1p (Fig. 6 A). 
Glutathione alone was also a poor activator of Ero1p. 10 mM 
GSH did not reduce regulatory bonds in either wild­type Ero1pc 
(Fig. 6 B, left) or Ero1pc­C100A­C105A (not depicted). However, 
a mixture of 10 mM GSH and Pdi1p maintained a pool of at 
least partially activated Ero1p (Fig. 6 B, right). The basis of Ero1p 
activation in the presence of Pdi1p and GSH appeared to be that 
cannot be transduced to activate Ero1p in the absence of Pdi1p. 
Pdi1p­depleted cells showed very slow activation of Ero1p even 
when they were treated with the reducing agent DTT, a condi­
tion that leads to rapid activation of Ero1p in Pdi1p­expressing 
cells (Fig. 5 E).
In the Pdi1p­depleted cells, a small amount of activated (re­
duced) Ero1p was detected (Fig. 5 D), and catalytically inactive 
Ero1 mutants Ero1p­C355S and Ero1p­C100A­C105A exhibited 
significantly more of the reduced forms (Fig. S5), suggesting that 
under conditions of Pdi1p depletion, although Ero1p can be re­
duced to some extent, most of the Ero1p remains in an oxidized 
state if autonomous reoxidation is possible. We tested the possi­
bility that the residual reduction of Ero1p in cells that had been 
depleted for Pdi1p was catalyzed by another PDI homolog. By 
conducting the depletion experiment in a strain depleted for the 
other homologs (mpd1, mpd2, eug1, eps1, pdi1, and 
CEN-PGAL1-PDI1), we found that reduced Ero1p formed to at 
least the same extent as in a pdi1 PGAL1-PDI1 strain (Figs. 5 D 
and S5), indicating that no other PDI family members contribute 
significantly to reduction of Ero1p regulatory bonds.
Glutathione acts synergistically with Pdi1p 
to activate Ero1p
The rapid Pdi1p­dependent reduction of Ero1p regulatory bonds 
that occurs in cells treated with DTT could be the result of a 
pool of reduced Pdi1p formed by direct reduction with DTT that 
had entered the ER. Alternatively, DTT treatment may produce 
Figure 6. A coupled Pdi1p/GSH system recapitulates Ero1p homeostasis in vitro. (A) Ero1p is only partially activated when Pdi1p is used as a substrate. 
1 µM Ero1pc was incubated with 25 µM reduced (red) Pdi1p. Ero1pc and Pdi1p were detected by immunoblotting with anti-Ero1p serum or anti-HDEL 
antibody. At the endpoint of in vitro oxidation (ox), Pdi1p is in a partially oxidized state, indicated by ox*. (B) Pdi1p is necessary for efficient reduction of 
Ero1pc by GSH. Ero1pc or a mixture of Ero1pc and oxidized Pdi1p was mixed with different concentrations of GSH for 1 h followed by TCA precipita-
tion, NEM modification, and Western analysis. (C) Pdi1p is necessary for efficient oxidation of GSH by Ero1pc. 10 mM GSH was incubated with 1 µM 
Ero1pc in the presence or absence of 10 µM oxidized Pdi1p. The amount of GSSG produced was measured after alkylating GSH followed by reduction 
with glutathione reductase and assay of free thiols with Ellman’s reagent. (D) The balance of GSH and GSSG can be established by the mixture of Ero1pc 
and Pdi1p. 10 µM Pdi1p and 5 µM Ero1pc were incubated with three different glutathione mixtures, 5 mM GSH, 4 mM GSH/0.5 mM GSSG, and 3 mM 
GSH/1 mM GSSG. The natural oxidation of 5 mM GSH without enzymes was also measured. The percentage of oxidized glutathione was calculated for 
the indicated time points. (C and D) Error bars represent the SEM generated by three independent experiments.
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However, oxidized Trx1 has no capacity to reoxidize the regu­
latory cysteines of Ero1p. Instead, oxidation of the regulatory 
cysteines is accomplished by Ero1p itself in a reaction that 
probably involves the transfer of a disulfide bond from the shut­
tle cysteines of one Ero1p protein molecule to the regulatory 
cysteines of another. Thus, the inactivation phase occurs by 
autonomous oxidation of Ero1p once reduced Trx1 has been 
depleted by being converted to the oxidized form.
A similar analysis for a reaction that contains Ero1p and 
its natural substrate Pdi1p revealed that Ero1p is never fully ac­
tivated in the presence of Pdi1p (Fig. 6 A). Whereas we initially 
thought that the inability of Pdi1p to activate Ero1p robustly 
was a consequence of some deficiency in the in vitro reaction, 
we now have evidence that the balance of the reduced and 
oxidized forms of Pdi1p is crucial in regulating Ero1p enzyme 
activity and faithfully reproduces the redox homeostasis set 
point of the ER.
Pdi1p has two redox­active domains containing the CxxC 
motifs. The a domain is not as efficiently oxidized by Ero1p as 
the a domain (Vitu et al., 2010). However, the a domain does 
appear to play a greater role than the a domain in oxidizing the 
Ero1p regulatory bonds; the partially oxidized a domain (Pdi1p­
SSCC) accelerates oxidation of Ero1p regulatory bonds more rap­
idly than the fully oxidized a domain (Pdi1p­CCSS). Given the 
relative redox potentials of the two domains, their propensity to be 
oxidized by Ero1p and their relative ability to oxidize the regu­
latory bonds of Ero1p provide a consistent explanation for why 
the a domain is only partly oxidized, whereas the a domain is 
fully oxidized in cells under standard conditions (Vitu et al., 
2010). In contrast to the yeast Pdi1p, the two active domains of 
the human PDI have similar reduction potentials, and the a  
domain is the one preferentially oxidized by Ero1­ (Wang et al., 
2009; Chambers et al., 2010). Therefore, it seems possible that 
the mechanism of Ero1­ regulation via the two domains of the 
human PDI is distinct from the one in yeast. Specificity in inter­
action between human and yeast Ero1 and PDI proteins has 
been demonstrated (Vitu et al., 2010; Masui et al., 2011). Com­
parison of the activity of human and yeast proteins in vitro 
shows that the highest enzyme activity is achieved using protein 
combinations of Ero1 and PDI from the same species (Araki 
and Nagata, 2011). Low catalytic activity was traced in part to 
a weaker binding affinity between human Ero1­ and yeast Pdi1p, 
relative to human PDI (Araki and Nagata, 2011). Whether the 
different redox potentials of the PDI domains in human and 
yeast PDI also contribute to the differences in Ero1 regulation 
between species remains to be assessed.
Several lines of evidence point to the existence of multiple 
disulfide relay pathways from Ero1p to Pdi1p. Best character­
ized is the flow of disulfides from the C352­C355 pair to Pdi1p 
via the C100­C105 shuttle cysteines. This pathway is necessary 
for full activity of Ero1pc in vitro and is necessary for cell via­
bility. Nevertheless, Ero1pc­C100A­C105A retains some activ­
ity in vitro and shows slow autonomous reoxidation, showing 
that a disulfide bond can be transferred, albeit slowly, from the 
active site to the regulatory disulfides without the action of the 
C100­C105 shuttle (Fig. 2 B). Moreover, in vivo experiments 
have shown that yeast cells with an ero1-C100A mutation are 
provided by a pool of GSH in great stoichiometric excess to Pdi1p, 
which allowed for a significant pool of reduced Pdi1p to be main­
tained. This pool of reduced Pdi1p in turn could reduce the regu­
latory bonds of Ero1p, thus overcoming the kinetic barrier for 
GSH to reduce the Ero1p regulatory bonds. In this coupled reac­
tion, oxidized glutathione (GSSG) was generated by the com­
bined action of Pdi1p and Ero1p (Fig. 6 C), and production of 
GSSG depended on Ero1p enzymatic activity because even in the 
presence of Pdi1p, catalytically inactive Ero1pc­C100A­C105A 
did not produce GSSG actively, whereas hyperactive Ero1pc­
C150A­C295A produced GSSG more rapidly than wild type 
(not depicted).
To investigate the effects of the balance of GSH to GSSG on 
Ero1p activity, we reconstituted an in vitro reaction in which re­
combinant Ero1p and Pdi1p were incubated in the presence of 
three different ratios of GSH/GSSG. When the reaction was be­
gun in the presence of GSH only, the rate of glutathione oxidation 
was initially rapid but then slowed. Evidently, the concomitant 
generation of GSSG by the action of Ero1p and Pdi1p eventually 
leads to inactivation of Ero1p (Fig. 6 D, 5 mM GSH curve). Intro­
duction of GSSG into the coupled reaction slowed the initial rate 
of GSH oxidation (compare the curves of 5 mM GSH with 8:1 and 
3:1 GSH/GSSG; Fig. 6 D). Taking the background of slow nonen­
zymatic generation of GSSG into account, the Ero1p and Pdi1p 
catalyzed oxidation of GSH stops at when the molar ratio of GSH/
GSSG is 3:1. Thus, this ratio of GSH/GSSG appears to be the 
approximate steady­state set point for the coupled reaction.
Discussion
A conserved protein disulfide relay system of the ER, consist­
ing of Ero1 and PDI, supports correct disulfide bond formation 
of secretory proteins (Sevier et al., 2001; Sevier and Kaiser, 
2006a; Appenzeller­Herzog et al., 2008; Braakman, 2009). In 
S. cerevisiae, the Ero1­PDI relay is essential for biosynthetic 
disulfide bond formation and is thus essential for cell viability 
(Frand and Kaiser, 1998; Pollard et al., 1998; Vitu et al., 2010). 
We previously showed that the activity of S. cerevisiae Ero1p is 
controlled by an autoregulatory feedback loop that involves the 
reduction and the reoxidation of three regulatory disulfide bonds 
(Sevier et al., 2007). Here, we show that not only is Pdi1p the 
major substrate of Ero1p in the disulfide relay system but that 
Pdi1p is also the primary regulator of Ero1p activity by its abil­
ity carry out dithiol/disulfide exchange with the regulatory 
bonds. We also show that the redox state of glutathione in the 
ER is important for setting the regulatory state of Pdi1p, and, in 
this way, the disulfide bond–generating activity of Ero1p is con­
trolled by the redox status of both Pdi1p and of glutathione.
In a reaction initiated by adding to Ero1p a stoichiometric 
excess of reduced Trx1, a model substrate, the regulatory bonds 
in Ero1p are rapidly reduced, and Trx1 is oxidized by active Ero1p. 
Once Trx1 has been oxidized, the regulatory bonds in Ero1p are 
reformed, and Ero1p returns to an inactive state. In this paper, 
we separated the activation and inactivation phases of this cycle 
to determine the biochemical requirements for each phase. 
As expected, the reduced form of Trx1 readily reduces regula­
tory bonds in Ero1p and is thus a potent activator of Ero1p. 
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(Appenzeller­Herzog et al., 2010). It seems likely that ER redox 
homeostasis is maintained by the same basic mechanism in yeast 
and mammalian cells.
Materials and methods
Protein expression and purification
The sequence coding Ero1pc (56–424) or Ero1pc mutants (Ero1pc-C100A-
C105A, Ero1pc-C355S, Ero1pc-C150A-C295A, Ero1pc-C90A-C349A, 
Ero1pc-C143A-C166A, and Ero1pc-C100A-C105A-C143A-C166A) was 
fused at the C terminus to His6-tagged MBP linked by the Tobacco etch virus 
(TEV) protease cleavage sequence (ENLYFQGS) inserted into the pET17b 
vector (EMD) between NdeI and XhoI restriction sites. We found that C355S 
was the only point mutation of the active-site cysteine pair (C352-C355) 
that could be produced in a soluble FAD-bound state. Ero1pc and all vari-
ants were overexpressed in Origami B(DE3) competent cells (EMD) by in-
duction with 0.4 mM IPTG supplemented with 10 µM FAD overnight at 
room temperature. Ero1pc fusion proteins with His6-tagged MBP were puri-
fied from cell lysates by affinity to amylose (New England Biolabs, Inc.) 
and then dialyzed into TEV cleavage buffer (50 mM Tris, pH 7.8, 0.5 mM 
EDTA, and 0.5 mM tris(2-carboxyethyl)phosphine). MBP-fused Ero1pc 
(MBP-Ero1pc) and Ero1pc-C100A-C105A were also expressed and puri-
fied as described for Ero1pc purification. Ero1pc was cleaved from His6-
tagged MBP by incubating with recombinant His6-tagged TEV protease 
(1:100 wt/wt protease to substrate; the TEV protease–encoding plasmid 
was provided by C. Hill, University of Utah, Salt Lake City, UT) for 15 h at 
25°C. Ero1pc and variants cleaved from His6-MBP were collected by flow-
ing through the HiTrap Ni2+ column (GE Healthcare) to remove uncleaved 
fusion protein, cleaved His6-tagged MBP, and TEV protease. Some Ero1pc 
variants (Ero1pc-C100A-C105A-C150A-C295A and Ero1pc-C100A-
C105A-C90A-C349A) were subcloned in pGEX-4T vector purified by flow-
ing though GSTrap (GE Heathcare) followed by thrombin cleavage for 
elution and secondary purification with the HiTrap Ni2+ column for removal 
of thrombin (Gross et al., 2004). All purified Ero1pc proteins were dia-
lyzed against PBS.
The sequence coding Pdi1p (31–522) or Pdi1p variants (C406S-
C409S for CCSS, C61S-C64S for SSCC, and C61S-C64S-C406S-C409S 
viable if they have the capacity to up­regulate Ero1p expression 
through unfolded protein response induction (Frand and Kaiser, 
2000), and overexpression of Ero1p­C100A­C105A­C150A­
C295A was able to partially suppress the temperature sensitiv­
ity of the ero1-1 strain (unpublished data).
The pathway of dithiol/disulfide exchange reactions used 
by Ero1p­C100A­C105A to oxidize Pdi1p remains to be deter­
mined. Considering that autonomous oxidation of the regulatory 
cysteines by Ero1p­C100A­C105A is possible, we hypothesize 
that the active­site disulfide bond C352­355 may first be trans­
ferred to regulatory cysteine pairs, and then Pdi1p could be oxi­
dized by reducing these regulatory bonds during the activation 
process of Ero1p. These pathways were revealed by experi­
ments with Ero1pc­C100A­C105A but are not limited to mutant 
Ero1p and are likely also used by wild­type Ero1p. By transfer­
ring one or two of the regulatory bonds to Pdi1p, Ero1p would 
have some capacity to oxidize a stoichiometric quantity of Pdi1p 
without any Ero1p becoming fully active. The C143­C166 bond 
may be the most labile regulatory bond, as its reduction is the 
first step of Ero1 activation by Pdi1p in vitro (Heldman et al., 
2010) and in turn could readily contribute to Pdi1p oxidation. 
This pathway may allow the disulfide relay system to respond 
to modest increases in load with a minimum of excess hydrogen 
peroxide generation.
When Ero1p is incubated with reduced Pdi1p and GSH, 
Ero1p can be shown to be catalytically active by its ability to oxi­
dize a stoichiometric excess of GSH, although little or no Ero1p 
can be detected in a state in which all regulatory cysteines are in 
a reduced state (Fig. 6 B). As previously noted (Heldman et al., 
2010), this observation indicates that the partially reduced forms 
of Ero1p have at least some oxidase activity. Thus, the regula­
tory bonds in Ero1p may act less like an on/off switch than a 
proportional controller with different degrees of activity accord­
ing to the redox states of the three regulatory bonds. We have 
not been able to devise a quantitative test of this attractive hy­
pothesis because it is not possible to isolate in pure form Ero1p 
in a partially reduced state.
Toward a biochemical understanding of the mechanism of 
Ero1p regulation in a highly simplified reaction, we success­
fully reconstituted the disulfide relay system and the basic prop­
erties of redox homeostasis in vitro with just their components, 
Ero1pc, Pdi1p, and glutathione (Fig. 6). The capacity of Pdi1p 
to sustain Ero1p in an activated state can be increased by addi­
tion of an excess of GSH in the in vitro reaction. This coupled 
reaction appears to approximate conditions in the ER (Hwang 
et al., 1992), in which transfer of disulfide bonds to nascent se­
cretory proteins and to GSH keeps enough Pdi1p in a reduced 
state to allow for some capacity to activate Ero1p. In the cou­
pled reaction, Ero1p enzyme activity is controlled by the ratio 
of GSH/GSSG, and a 3:1 ratio of GSH/GSSG appears to be close 
to the steady­state set point at which Ero1p can be activated. 
Pdi1p, which has both reductase and isomerase activities, can 
serve as the key link between thiol substrates, including gluta­
thione, and Ero1p to activate the disulfide relay system only 
when substrates are present (Fig. 7). In the mammalian cell, it 
has also been suggested that oxidation of PDI and glutathione 
is well regulated by an equilibrium between Ero1­ and PDI 
Figure 7. A balance between reduced and oxidized Pdi1p determines 
ER redox homeostasis. The thiol substrates (reduced protein thiols or re-
duced glutathione) present in the ER can be oxidized by Pdi1p, leading 
to formation of reduced Pdi1p. If sufficient reduced Pdi1p has formed, 
Ero1p is activated by direct reduction of the Ero1p regulatory bonds by 
reduced Pdi1p. Once activated, Ero1p oxidizes Pdi1p until a steady-state 
balance of oxidized and reduced Pdi1p is reestablished. The balance of 
reduced and oxidized Pdi1p determines the degree of Ero1p activation; 
once reduced Pdi1p has declined sufficiently, autonomous oxidation of 
the regulatory bonds of Ero1p will lead to Ero1p inactivation, preventing 
overoxidation of the ER. Under hyperoxidizing conditions, oxidized Pdi1p 
would rapidly inactivate Ero1p.
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was calculated by dividing reduced band intensity with the sum of reduced 
and oxidized band intensity.
To determine the effect of hydrogen peroxide on the oxidation state of 
Ero1p regulatory bonds (Fig. S1), 1 µM Ero1pc was incubated with 100 µM 
reduced His6-tagged Trx1 in PBS containing 0.5 mM EDTA for 2 min, and 
Trx1 was selectively removed by affinity for Ni2+ beads. To remove hydro-
gen peroxide generated during action of Ero1p oxidase, 80 µg/ml cata-
lase was added to the reaction. Removal of hydrogen peroxide by catalase 
was confirmed by measuring the amount of hydrogen peroxide in the reac-
tion with Amplex UltraRed reagent (Invitrogen). 1 µM Ero1pc was incu-
bated with 100 µM reduced thioredoxin, 50 µM Amplex red, and 0.1 U/ml 
HRP in the presence or absence of 80 µg/ml catalase for 30 min at room 
temperature. Fluorescence was measured in a microplate reader with 
wavelength settings of 530/590 nm. Inactivation of Ero1p under anaero-
bic conditions was analyzed as described above except being performed 
in the anaerobic chamber flowing N2 and CO2 gases. To test whether 
exogenous hydrogen peroxide or oxidized Pdi1p can promote inactivation 
of Ero1p, 100 µM hydrogen peroxide or 20 µM oxidized Pdi1p was 
added to Ero1pc, Ero1pc-C100A-C105A, or Ero1pc-C355S after Trx1 de-
pletion. Oxidation states of Ero1pc and its mutants were analyzed after 
cysteine modification with 1 mM AMS by nonreducing SDS-PAGE and 
immunoblotting with anti-Ero1p serum.
The oxidation states of each catalytic domain of recombinant Pdi1p 
were determined by introducing a thrombin cleavage site that allows sepa-
ration of the two catalytic domains (Fig. S2). The sequence coding N-terminal 
His6-tagged Pdi1p (31–522) with a thrombin recognition sequence in the 
X-linker was subcloned from pSK42 (Vitu et al., 2010) for E. coli expres-
sion. His6-Pdi1p-thrombin was overexpressed in BL21(DE3)pLysS compe-
tent cells by IPTG and purified from cell lysates with the HiTrap Ni2+ column. 
Purified His6-Pdi1p-thrombin was dialyzed into PBS. 10 µg His6-Pdi1p-thrombin 
was incubated with 1 mM AMS for 30 min at room temperature followed 
by treatment with 0.1 µg thrombin supplemented with 1 mM CaCl2 for 1 h 
at 37°C. Fully reduced Pdi1p control was prepared by treatment with 
10 mM DTT for 30 min at room temperature. DTT was removed by using 
Bio-Spin 6. AMS-modified and thrombin-digested samples were analyzed 
by nonreducing SDS-PAGE.
The oxidation state of newly synthesized CPY in the Pdi1p-depleted 
ER was analyzed in pdi1 cells with galactose-inducible PDI1 grown to the 
exponential phase for 15 h in glucose medium to deplete Pdi1p. Cells 
were suspended in SMM-met, pulse labeled for 10 min at 30°C, and lysed 
in the presence of 10% chilled TCA to block disulfide exchange. After AMS 
modification, CPY was immunoprecipitated and resolved by reducing 
SDS-PAGE. A fully reduced CPY control was prepared by treating cells 
with 10 mM DTT for 15 min before cell lysis.
Reoxidation of Ero1pc after thioredoxin depletion
1 µM Ero1pc was reduced by incubation with 100 µM reduced His6-tagged 
Trx1 for 2 min and then passed through Ni2+ beads to remove Trx1. At 
times after Trx1 depletion, the reaction was quenched by mixing with SDS 
sample buffer containing 1 mM AMS. Depletion of Trx1 was confirmed by 
analysis with nonreducing SDS-PAGE. When necessary, 40 µM oxidized 
Trx1, 20 µM oxidized Pdi1p, or 20 µM oxidized Pdi1p mutant was added 
into Ero1pc or Ero1pc mutants immediately after Trx1 depletion.
Purification of mixed disulfides from yeast
CKY1090 expressing His6-Pdi1p was transformed with pSK64 [ero1-
C100A-C105A-flag], pDPS51 [ero1-C100A-C105A-C150A-C295A-flag], 
pDPS49 [ero1-C100A-C105A-C90A-C340A], and pDPS50 [ero1-C100A-
C105A-C143A-C166A]. Exponentially grown cells were lysed by agita-
tion with glass beads in the presence of chilled 10% TCA. TCA-precipitated 
protein pellets were washed with acetone and redissolved with 2% SDS and 
50 mM Tris, pH 8.0, containing 50 mM NEM to block free cysteines. For effi-
cient affinity purification, SDS was removed by SDS-Out reagent (Thermo 
Fisher Scientific). After clarification by centrifugation, Ero1p-C100A-C105A-
flag was released from anti-flag affinity beads using 100 µg/ml flag pep-
tide (Sigma-Aldrich) followed by deglycosylation with PNGaseF for 3 h at 
37°C. Samples purified by affinity to anti-flag beads were passed through 
an Ni2+ column to capture mixed disulfides with His6-Pdi1p. Both Ni2+ 
unbound fraction and bound fraction were collected and analyzed by non-
reducing SDS-PAGE and immunoblotting with anti-flag (Sigma-Aldrich) or 
anti-Pdi1p.
Depletion of Pdi1p and glutathione in yeast
To determine the oxidation states of Ero1p and mutants in Pdi1p- or 
glutathione-depleted cells, pSK63, pSK64, and pSK66 were transformed into 
CKY1088 and/or CKY1089. Cells exponentially grown in SMM containing 
for SSSS) tagged with His6 at the N terminus was inserted into pET20b be-
tween NdeI and SacI restriction sites. Recombinant His6-tagged Pdi1p, 
Pdi1p variants, and His6-tagged E. coli thioredoxin (Trx1; Sevier and Kaiser, 
2006b) were overexpressed in BL21(DE3)pLysS competent cells (EMD) by 
induction with 0.4 mM IPTG for 5 h at 37°C and purified from cell lysates 
by affinity to the HiTrap Ni2+ column. Purified, naturally oxidized Pdi1p 
and Trx1 were dialyzed into PBS. Reduced forms of Pdi1p and Trx1 were 
prepared by incubating with 10 mM DTT for 30 min at room temperature 
and removing DTT with Micro Bio-Spin 6 (Bio-Rad Laboratories).
Yeast strains and plasmids
CKY1044 and CKY1045 and MATa and MAT pdi1::KanMX strains 
covered by URA3 CEN PDI1 plasmid pCS213 have been previously de-
scribed (Vitu et al., 2010). To facilitate scoring of crosses with the pdi1 
strain, a NatMX-marked pdi1 strain was constructed by swapping the 
KanMX marker in CKY1045 with a NatMX4 cassette by homologous re-
combination (Goldstein and McCusker, 1999). Individual disruptions of the 
genes encoding the yeast PDI homolog proteins were made by one-step 
gene replacement of the entire ORF with KanMX by homologous recombina-
tion. The compound deletion strain CKY1086 with the genotype MATa GAL2 
ura3-52 leu2-3,112 pdi1::NatMX mpd1::KanMX mpd2::KanMX 
eug1::KanMX eps1::KanMX [pCS213] was constructed by sequential 
rounds of mating, sporulation, and scoring of the initial individual disruption 
mutant strains. Disruption of all five genes encoding the PDI1 homologs in 
CKY1086 was confirmed by PCR analysis. Some pdi1 strains also con-
tained a genomic-tagged copy of BGL2. Tagging of BGL2 with a triple HA 
epitope at its C terminus was performed by homologous recombination with 
a 3HA-KanMX6 module (Longtine et al., 1998). To construct the MATa GAL2 
ura3-52 leu2-3,112 pdi1::NatMX BLG2:HA-KanMX [pCS213] double 
mutant (CKY1087), individual pdi1 and BLG2:HA strains were mated, 
and an MATa NatMX+ KanMX+ segregant was selected after sporulation. 
Viability of CKY1086 and CKY1087 depends on a plasmid-borne PDI1 gene 
provided by plasmid pCS213. CKY1088 and CKY1089 were generated 
by transformation of CKY1086 or CKY1087, respectively, with the pSK65 
[CEN LEU2 PGAL1-PDI1] followed by selection against pCS213 by plating on 
supplemented minimal medium (SMM) with 5-FOA. CKY1090 was created 
by transformation of CKY1044 with pSK2 [CEN LEU2 His6-PDI1] followed 
by selection against pCS213 with 5-FOA.
To create pSK2 [CEN LEU2 His6-PDI1], the sequence coding HHHH-
HGG was inserted right after the signal sequence (1–22) by introducing 
the NheI restriction site in pCS463, which contains the PDI1 coding region 
and 875 and 150 bp of the 5 and 3 untranslated regions. Plasmid 
pSK65 [CEN LEU2 PGAL1-PDI1] contains the PDI1 coding region and 60 
and 150 bp of the 5 and 3 untranslated regions under the GAL1 pro-
moter. ERO1-coding URA3 2µ plasmids pSK63 [ERO1-flag], pSK64 [ero1-
C100A-C105A-flag], pDPS51 [ero1-C100A-C105A-C150A-C295A-flag], 
pDPS49 [ero1-C100A-C105A-C90A-C340A], pDPS50 [ero1-C100A-
C105A-C143A-C166A], and pSK66 [ero1-C355S-flag] were generated by 
insertion of sequence-encoding flag tag right after the last codon using the 
NotI restriction site and subcloning or site-directed mutagenesis based on 
the previously reported plasmid pAF84 (Frand and Kaiser, 1998).
Analysis of protein oxidation states
For reduction of Ero1p regulatory bonds in vitro, 1 µM Ero1pc or its variants 
were incubated with 50 or 20 µM reduced Trx1, reduced Pdi1p, or reduced 
Pdi1p mutants in PBS containing 0.5 mM EDTA. After incubation at 25°C, 
the reactions were quenched by mixing with 1× SDS-AMS (4-acetamido-
4-maleimidylstilbene-2,2-disulfonic acid) buffer (1× SDS sample buffer 
without reducing agent and 1 mM AMS [Invitrogen]), which alkylates free 
cysteine thiols and adds one 500-D moiety to each free thiol. For reac-
tions that contained glutathione or DTT, proteins were first precipitated by 
10% chilled TCA. Protein precipitants were washed with 0°C acetone and 
were redissolved with 1× SDS-AMS buffer. Ero1p and Pdi1p were ana-
lyzed by nonreducing SDS-PAGE followed by immunoblotting with anti-
Ero1p serum or anti-HDEL (Santa Cruz Biotechnology, Inc.). The oxidation 
state of Trx1 was analyzed by nonreducing SDS-PAGE followed by stain-
ing with SimplyBlue SafeStain (Invitrogen).
The in vivo oxidation state of Ero1p was assessed in cells growing 
in SMM medium incubated with 0, 0.2, or 1 mM DTT for 30 min and then 
lysed in the presence of chilled 10% TCA by agitating with glass beads. 
Protein pellets from cell lysates were washed with chilled acetone and re-
dissolved with 1× SDS-AMS buffer. Oxidation states of Ero1p and variants 
were analyzed by nonreducing SDS-PAGE and immunoblotting with anti-
Ero1p. Immunoblots were visualized with an Odyssey imaging system (LI-COR 
Biosciences). The fully reduced or the oxidized band of Ero1pc was quantified 
by the Odyssey program (v2.0; LI-COR Biosciences), and reduced fraction 
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1.5% galactose and 1% raffinose were incubated in SMM containing 2% 
glucose for 15 h to shut off expression of Pdi1p. Glutathione was depleted 
by growing cells in the presence of 5 mM BSO, an inhibitor of glutathione 
biogenesis, for 15 h. Pdi1p depletion was confirmed by immunoblotting 
with anti-Pdi1p (Fig. 5 E), and glutathione depletion was confirmed using 
Ellman’s reagent.
The maturation of CPY was evaluated in pdi1 cells with galactose-
inducible PDI1 grown to exponential phase for 15 h in glucose medium to 
deplete Pdi1p. For fully reduced cell environment, cells were incubated 
with 1 mM DTT for 1 h after a 14-h incubation in glucose medium. Cell lysates 
was prepared in the presence of chilled 10% TCA, and mature and immature 
CPY were analyzed by immunoblotting with anti-CPY serum.
Measurement of oxidized glutathione
GSSG produced by Ero1pc and Pdi1p was measured by using Ellman’s re-
agent (5,5-dithiobis-(2-nitrobenzoic acid) [DTNB]). 1 µM Ero1pc, Ero1pc-
C150A-C295A, or Ero1pc-C355S was incubated with 10 mM GSH with 
or without 10 µM oxidized Pdi1p. For extended reaction, 5 mM GSH, 
4 mM GSH/0.5 mM GSSG, or 3 mM GSH/1 mM GSSG was mixed with 
Ero1p and Pdi1p. At various time points after mixing, 10 µl of reactants 
was quenched by chilled 5-sulfosalicylic acid (1% final concentration), 
and precipitated protein pellet was removed. GSH was alkylated by 2% 
2-vinylpyridine after neutralizing sulfosalicylic acid with a drop of trietha-
nolamine (Sigma-Aldrich) for 1 h at 25°C followed by a 20-fold dilution in 
DTNB reaction buffer containing 100 mM sodium phosphate, pH 7.0, 1 mM 
EDTA, 0.2 mM DTNB, and 0.2 mM NADPH. The change in absorbance at 
405 nm was recorded after adding 1 U of glutathione reductase.
Online supplemental material
Fig. S1 shows that autonomous oxidation and inactivation of Ero1p is not 
a side effect of hydrogen peroxide produced by aerobic catalysis by 
Ero1p. Fig. S2 shows that the endpoint of air oxidation yields a form of 
recombinant Pdi1p with the a domain almost fully oxidized, and the a 
domain is partially oxidized. Fig. S3 shows that air-oxidized Pdi1p can 
contribute to the oxidation of the Ero1p regulatory bonds. Fig. S4 shows 
that when cells are depleted of Pdi1p by growing pdi1 cells with glucose-
repressible PDI1 in glucose medium, newly synthesized CPY remains largely 
in a reduced state. Fig. S5 shows that when cells are depleted of Pdi1p, 
autonomous oxidation of the regulatory bonds of Ero1p can occur. This 
oxidation requires active-site cysteine C355 but does not require the shuttle 
cysteines C100 and C105. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/jcb.201110090/DC1.
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